📬 Lung/Head and Neck/Thymoma Intelligence Digest — Week 2026-W34
Osimertinib plus chemotherapy doubled PFS in EGFR/TP53 co-mutated NSCLC, REZILIENT3 met its PFS endpoint in EGFR exon 20 insertion NSCLC, SKYSCRAPER-03 added another negative TIGIT phase III, and CheckMate 77T biomarker data landed in Nature.
⚡ TL;DR
📄 Publications
- SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. — Median IRF-assessed PFS in PD-L1+ patients was 19.4 months with tiragolumab plus atezolizumab versus 16.6 months with durvalumab (HR 0.96; p = 0.76)
- Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. — Median PFS was 34.0 vs 15.6 months with osimertinib plus chemotherapy versus osimertinib alone (HR 0.44, P < .001)
🐦 Twitter / 🦋 Bluesky
- CheckMate 77T biomarker analysis in Nature: ctDNA clearance and tumor-suppressor alterations track perioperative nivolumab benefit — Pre-surgical ctDNA clearance was 66% with perioperative nivolumab versus 38% with placebo, and 50% of clearance patients achieved pCR with nivolumab
- Osimertinib plus chemotherapy doubles PFS in EGFR/TP53 co-mutated NSCLC, reopening the de-escalation question — In EGFR/TP53 co-mutated NSCLC, osimertinib plus chemotherapy gave median PFS 34.0 vs 15.6 months versus osimertinib alone (HR 0.44, P<0.001)
- Nature Cancer review on intratumor heterogeneity and tumor evolution puts lung cancer at the center — Different populations of cancer cells can exist within one tumor and evolve over time, including under the pressure of treatment, and a Nature Cancer review examines how tracking that evolution could improve diagnosis, monitoring and treatment
- REZILIENT3 meets its PFS endpoint: zipalertinib plus chemotherapy becomes the third regimen to beat chemo alone in EGFR exon 20 insertion NSCLC — Adding zipalertinib to first-line chemotherapy significantly improved PFS over chemotherapy alone in advanced NSCLC with an EGFR exon 20 insertion mutation
- International consensus issues 55 recommendations for managing datopotamab deruxtecan toxicity in NSCLC — An international steering committee issued 55 recommendations for preventing and managing Dato-DXd side effects in advanced/metastatic NSCLC, covering oral mucositis, ILD/pneumonitis, ocular surface events and nausea and vomiting
Full details below ↓
📄 What's Being Published
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation. — Wakelee H A et al., Ann Oncol
In PD-L1-positive patients, median IRF-assessed PFS was 19.4 months with tiragolumab plus atezolizumab versus 16.6 months with durvalumab (stratified HR 0.96; 95% CI 0.75–1.23; p = 0.76). In PD-L1 all-comers, median PFS was 14.2 versus 13.8 months (stratified HR 1.00; 95% CI 0.84–1.19) and median OS was 45.6 versus 45.8 months (stratified HR 0.98; 95% CI 0.80–1.20), with no benefit in any analyzed population.
Clinical bottom line: The published SKYSCRAPER-03 data confirm tiragolumab plus atezolizumab is no better than durvalumab consolidation after chemoradiation; clinicians are now arguing that TIGIT trials should stop selecting patients by PD-L1.
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. — Rohrberg Kristoffer S et al., Clin Cancer Res
At the recommended phase II dose of 750 mg Q3W, the anti-PD-1/TIGIT bispecific rilvegostomig produced an objective response rate of 5.6%, a 6-month disease control rate of 31.5%, and a median PFS of 3.8 months, with a 12-month PFS of 11.9%. Grade 3 treatment-related adverse events occurred in 8.4% of patients and treatment-related discontinuations in 2.4%.
Clinical bottom line: Rilvegostomig is tolerable but produced only a 5.6% response rate in checkpoint-inhibitor-experienced PD-L1-positive NSCLC; its fate rests entirely on the checkpoint-naive cohorts.
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. — Zhou Ting et al., JAMA
Among 294 treatment-naive patients with stage IV or recurrent nonsquamous NSCLC harboring concurrent TP53 and EGFR-sensitizing mutations, median PFS was significantly longer with osimertinib plus chemotherapy than with osimertinib monotherapy (34.0 vs 15.6 months; difference 18.4 months [95% CI 9.9–22.3]; HR 0.44 [95% CI 0.32–0.60]; P < .001). Overall survival data remained immature at 30.6% maturity, though a trend toward OS benefit with the combination was observed.
Clinical bottom line: TP53 co-mutation now provides prospective, randomized grounds for adding chemotherapy to first-line osimertinib; the toxicity cost and immature OS mean the harder question is which EGFR-mutant patients can safely skip intensification.
Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid. — Ross Jessica S et al., J Thorac Oncol
In DLL3-high pulmonary carcinoid, tarlatamab produced a response rate of 8/11 (73%), including one patient with central nervous system-only disease, and a disease control rate of 11/11 (100%). Cytokine release syndrome occurred in cycle 1 in 9/11 (82%) patients, including 2 with grade 3 CRS.
Clinical bottom line: The published series confirms tarlatamab activity in DLL3-high pulmonary carcinoid; the discussion has shifted to whether the 82% CRS rate reflects uniformly high DLL3 expression rather than carcinoid biology.
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial. — Li Zi-Ming et al., Cancer Cell
Among 236 treated patients, the EGFR-directed ADC SYS6010 produced an objective response rate of 34.7% in EGFR-mutant NSCLC after EGFR TKIs and platinum chemotherapy, 45.7% after EGFR TKIs alone, 20.0% in EGFR wild-type squamous NSCLC, and 35.7% in EGFR wild-type non-squamous NSCLC; median PFS was 7.6 months and median OS 19.4 months in the TKI-plus-platinum cohort. Grade ≥3 treatment-related adverse events occurred in 57.2% of patients, including neutropenia in 30.9%, leukopenia in 25.0%, and thrombocytopenia in 17.4%.
Clinical bottom line: SYS6010 produces response rates in the 35–46% range after EGFR TKI failure, but its myelosuppression profile is heavy enough that dose and schedule will decide whether it can compete with existing post-TKI options.
The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations. — Repetto Matteo et al., Clin Cancer Res
Across 68,920 tumor-normal paired samples, SMARCA4 alterations were most frequent in thymic epithelial tumors (10.7%) and NSCLC (7.1%); class 1 and class 2 alterations occurred in 2.9% and 0.7% of tumors, respectively. In a phase I trial of the BRM degrader PRT3789, patients with monoallelic class 2 SMARCA4 alterations and preserved BRG1 expression achieved clinical benefit, including one complete response.
Clinical bottom line: SMARCA4 reporting should specify mutation class and allelic status, because those features—not the presence of an alteration alone—identify the thymic and lung tumors likely to respond to BRM-targeted degraders.
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L. — Subbiah Vivek et al., Clin Cancer Res
Among 34 eligible patients, no complete or partial responses were observed, yielding an ORR of 0%; median PFS was 1.7 months (90% CI 1.1–2.2) and median OS was 3.5 months (90% CI 1.9–5.4). Twenty patients (57%) experienced grade 3 toxicities and one patient (3%) experienced grade 4 toxicity.
Clinical bottom line: Single-agent ERK inhibition with ulixertinib is a dead end for BRAF fusions and non-V600 mutations; these alterations need combination or class-specific strategies rather than pathway-downstream monotherapy.
Prognostic Significance of Spread Through Airspaces (STAS) in Stage Ia/bN0 Non-small Cell Lung Cancer - An Evaluation in the JCOG0802/WJOG4607L Clinical Trial Patients. — Yatabe Yasushi et al., J Thorac Oncol
STAS was identified in 227 of 593 cases (38.3%) and was significantly associated with shorter relapse-free survival (HR 2.204; p < 0.001) and overall survival (HR 1.917; p < 0.001). STAS was also associated with higher local recurrence after both lobectomy and segmentectomy (p = 0.012 and p = 0.002, respectively).
Clinical bottom line: STAS and grade 3 histology should be reported routinely in stage IA resections, because they mark local recurrence risk after both segmentectomy and lobectomy in the JCOG0802 population.
DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. — Zhao Yuanyuan et al., J Immunother Cancer
In 60 patients with previously untreated extensive-stage SCLC, durvalumab plus olaparib maintenance produced an ORR of 73.3%, median PFS of 6.8 months, median OS of 14.6 months, and a 12-month alive-and-progression-free rate of 25.0%. Multi-omics profiling identified a hypomethylation subgroup (cluster 1) associated with significantly improved survival outcomes.
Clinical bottom line: Durvalumab plus olaparib maintenance produces unremarkable overall numbers in extensive-stage SCLC; the real finding is that DNA methylation status—not clinical features—separates the patients who benefit from PARP-plus-immunotherapy.
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
CheckMate 77T biomarker analysis in Nature: ctDNA clearance and tumor-suppressor alterations track perioperative nivolumab benefit
Pre-surgical ctDNA clearance was 66% with perioperative nivolumab versus 38% with placebo, and 50% of ctDNA-clearance patients achieved pCR with nivolumab; separately, patients with KEAP1/STK11/CDKN2A/SMARCA4 alterations had prolonged EFS with nivolumab (HR 0.48) despite historically poor prognosis. Patients who developed postoperative MRD all recurred—a strong prognostic signal—yet clinicians note that prospective trials are still needed to prove predictive utility before MRD status guides adjuvant decisions. The analysis reports ctDNA clearance, post-surgical MRD, whole-exome sequencing, and patient-reported outcomes together in one correlative package, prompting oncologists to describe it as setting the bar for translational correlates in phase 3 cancer trials. The central debate is whether perioperative ctDNA clearance is ready to guide adjuvant decisions in resectable NSCLC, or whether it remains prognostic-only until a prospective trial randomizes on it.
Discussed by: @StephenVLiu, @FordePatrick, @HHorinouchi, @ErulEnes, @EladSharonMD
Osimertinib plus chemotherapy doubles PFS in EGFR/TP53 co-mutated NSCLC, reopening the de-escalation question
In EGFR/TP53 co-mutated NSCLC, osimertinib plus chemotherapy gave a median PFS of 34.0 versus 15.6 months compared with osimertinib alone (HR 0.44, P < 0.001), with median duration of response more than doubling (32.7 vs 15.3 months) and consistent benefit across subgroups including patients with brain metastases. The trial enrolled 294 treatment-naive patients with stage IV/recurrent nonsquamous NSCLC carrying EGFR Ex19del/L858R plus a concurrent TP53 mutation; first-line osimertinib plus chemotherapy was associated with longer PFS but also greater toxicity. An accompanying JAMA editorial argues that TP53 is clinically relevant but its absence alone does not justify de-escalation, and calls for prospective de-escalation strategies. The core question is whether a TP53 co-mutation now decides who receives upfront chemotherapy with osimertinib, and whether TP53 wild-type patients can be spared intensification without prospective de-escalation data.
Discussed by: @M_Torasawa, @OncoAlert, @DrJNaidoo, @JAMA_current
Nature Cancer review on intratumor heterogeneity and tumor evolution puts lung cancer at the center
A Nature Cancer review examines how different populations of cancer cells can exist within a single tumor and evolve over time—including under the pressure of treatment—and how tracking that evolution could lead to better ways to diagnose, monitor, and treat cancer. Lung cancer research has been central to building this understanding of intratumor heterogeneity. The practical question for clinicians is how often molecular reassessment should be repeated during systemic therapy in lung cancer if tumor evolution under treatment is the rule rather than the exception.
Discussed by: @EladSharonMD, @lungcancereurope.bsky.social
REZILIENT3 meets its PFS endpoint: zipalertinib plus chemotherapy becomes the third regimen to beat chemo alone in EGFR exon 20 insertion NSCLC
The phase III REZILIENT3 trial met its primary endpoint: adding zipalertinib to first-line chemotherapy significantly improved PFS over chemotherapy alone in advanced NSCLC with an EGFR exon 20 insertion mutation, making it the third phase 3 regimen to beat chemotherapy alone on PFS in this setting, after PAPILLON and WU-KONG28. The announcement is topline only—no median PFS, no hazard ratio, and no ORR have been released, and zipalertinib remains investigational with full results to be presented at a medical meeting. None of the three regimens has shown a clear OS benefit, and there are no head-to-head data between them; zipalertinib will compete with amivantamab and sunvozertinib in exon 20 insertion disease, with OS data pending. The unresolved question for oncologists is how first-line choice should be made among three chemotherapy-combination regimens all positive on PFS, but none on OS, and none compared directly.
Discussed by: @StephenVLiu, @M_Torasawa, @YGaritaonaindia, @mgonzalezvelMD, @DrSanjayPopat
International consensus issues 55 recommendations for managing datopotamab deruxtecan toxicity in NSCLC
An international steering committee issued 55 recommendations for preventing and managing datopotamab deruxtecan (Dato-DXd) side effects in advanced/metastatic NSCLC, covering oral mucositis, ILD/pneumonitis, ocular surface events, and nausea and vomiting, with early detection, proactive patient communication, and multidisciplinary care identified as essential to protecting quality of life. Separately, AI-based automated image analysis reports that TROP2 QCS-NMR positivity is predictive of longer PFS in lung cancer, adding a potential biomarker dimension to patient selection. The question for clinics is whether TROP2 ADC prescribing now requires a formal toxicity-management pathway—incorporating mucositis, ILD, and ocular surveillance—built into routine practice.
Discussed by: @herbloong, @DFCI_BreastOnc
Twice-daily radiotherapy for limited-stage SCLC: Dutch real-world data show a survival split by age
Real-world data on once- or twice-daily radiotherapy in limited-stage SCLC show a clear age-dependent split: in patients under 70, twice-daily (BID) radiotherapy achieved a median OS of 36.0 months versus 22.2 months with once-daily (OD) schedules, without increased severe 90-day acute toxicity. In patients aged 70 and older, there was no significant survival difference between BID (21.8 months) and OD (24.3 months), and older patients treated with BID showed numerically higher toxicity levels. The debate for radiation oncologists is whether twice-daily thoracic radiotherapy should be reserved for fit patients under 70, and whether dose escalation beyond 45 Gy is ready to be offered outside a trial.
Discussed by: @FuenteApolo, @FuenteApolo
Trastuzumab rezetecan reports a 91.7% response rate in HER2-high salivary gland carcinoma
Trastuzumab rezetecan produced an ORR of 91.7% in HER2-high and 45.5% in HER2-low advanced salivary gland carcinoma, with median PFS not reached and 12.7 months, respectively. Head and neck clinicians place this result in the context of three biomarker-directed readouts in the past month—noting that all three targets (BRAF, AR, HER2) were validated first in other diseases (melanoma, prostate, and breast, respectively) before being applied in thyroid and salivary gland cancer. The question is whether a 45.5% response rate in HER2-low disease justifies HER2 immunohistochemistry on every advanced salivary tumor, not just the HER2-high ones.
Discussed by: @EladSharonMD, @Jdcramer, @OncLive
🔥 Top Ranked Tweets
OncoAlert @OncoAlert
RT @RManochakian: 🔥🚨@OncoAlert Hot off the press.
‼️@JazzPharma plans to ask @US_FDA to withdraw:
👎🏻🛑#Lurbinectedin (#Zepzelca) approval in 2nd line Tx of #SmallCell #LungCancer (#SCLC).
This is based on #Negative #Lagoon phase 3 trial that showed NO #OS benefit.
👇🏻
https://t.co/XtpPBWXT7s https://t.co/hxU8kEb6U4
🔖 3 ❤️ 33 🔁 11 👁 5,850
Elad Sharon @EladSharonMD
RT @LauraAlderMD: 🚨 Jazz + FDA are withdrawing lurbinectedin's accelerated approval in 2L metastatic SCLC after LAGOON missed OS.
So what do we actually do after tarlatamab, or where clinical trial / tarlatamab isn't available/feasible? Will payers still cover lurbinectedin off-label?
Very eagerly awaiting the ADCs: I-DXd (B7-H3), DLL3- and SEZ6-directed agents.
How are you sequencing relapsed SCLC right now? 👇
🔖 19 ❤️ 67 🔁 17 👁 5,708
Oncology Brothers @OncBrothers
RT @LauraAlderMD: 🚨 Jazz + FDA are withdrawing lurbinectedin's accelerated approval in 2L metastatic SCLC after LAGOON missed OS.
So what do we actually do after tarlatamab, or where clinical trial / tarlatamab isn't available/feasible? Will payers still cover lurbinectedin off-label?
Very eagerly awaiting the ADCs: I-DXd (B7-H3), DLL3- and SEZ6-directed agents.
How are you sequencing relapsed SCLC right now? 👇
🔖 19 ❤️ 67 🔁 17 👁 5,708
OncoAlert @OncoAlert
RT @StephenVLiu: Nature publication today from Dr. Tina Cascone et al with tremendous detail on biomarkers from CheckMate 77T predicting benefit from perioperative nivolumab in patients with resectable NSCLC. Amazing amount of detailed data in this @Nature paper.
https://t.co/Sb0H4YOpxz
🔖 49 ❤️ 98 🔁 37 👁 11,373
Stephen V Liu, MD @StephenVLiu
Nature publication today from Dr. Tina Cascone et al with tremendous detail on biomarkers from CheckMate 77T predicting benefit from perioperative nivolumab in patients with resectable NSCLC. Amazing amount of detailed data in this @Nature paper.
https://t.co/Sb0H4YOpxz
🔖 49 ❤️ 98 🔁 37 👁 11,375
OncoAlert @OncoAlert
RT @DrRishabhOnco: 🧬 Should TP53 co-mutation push us toward upfront chemotherapy in EGFR-mutant NSCLC?
A randomized phase III trial suggests YES: in EGFR + TP53 co-mutated advanced NSCLC, adding chemotherapy to osimertinib more than doubled median PFS.
📌 Study
294 treatment-naïve patients with stage IV/recurrent nonsquamous NSCLC, EGFR Ex19del/L858R + concurrent TP53 mutation.
🔹 Osimertinib + carboplatin/pemetrexed ×4 → osimertinib + pemetrexed maintenance
vs
🔹 Osimertinib alone
📊 Key results
🔥 mPFS: 34.0 vs 15.6 months
HR 0.44 (95% CI 0.32–0.60), P<.001
🎯 ORR: 82.9% vs 71.6%
⏳ Duration of response: 32.7 vs 15.3 months
👀 Interim OS:
48.4 vs 36.5 months
HR 0.57 (95% CI 0.38–0.88)
But OS remains immature at only 30.6% maturity.
⚠️ The price: toxicity
Grade ≥3 TRAEs: 62.4% vs 14.9%
1 treatment-related death occurred with combination therapy.
💡 Why it matters
This is prospective randomized evidence that TP53 may help identify the high-risk EGFR-mutant population most likely to justify upfront treatment intensification, rather than giving chemotherapy to every patient with EGFR-mutant disease.
⚠️ Limitations
Single-region Chinese study, open-label design, immature OS and additional genomic/resistance analyses still pending.
✅ Clinical verdict: PROMISING & potentially practice-informing
EGFR alone tells us what to target.
TP53 may increasingly tell us how aggressively to target it.
@ASCO @oncoalert
#LungCancer #NSCLC #EGFR #Oncology
🔖 24 ❤️ 59 🔁 24 👁 3,592
Aya Mohamed | MSc, MD 🎗 @Dr_Oncologista
RT @OncoAlert: 🫁 When adding another immunotherapy agent sounds promising—but the phase III data say otherwise—what should we learn?
https://t.co/MZfaljl0PP
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation
SKYSCRAPER-03 compared tiragolumab plus atezolizumab with durvalumab as consolidation therapy after chemoradiation for unresectable stage III #NSCLC ➡️In PD-L1–positive patients, progression-free survival was 19.4 versus 16.6 months, but the difference was not statistically significant.
✅ Overall survival was also similar between groups, with no new safety concerns. The primary endpoint was not🚫 met, indicating that adding tiragolumab did not provide additional benefit over durvalumab. #LungCancer
@DrSanjayPopat
@karenkellymd
@BairdAM
@MLJohnsonMD2
@k_cupp_
Pinging 🚨OncoAlert Faculty
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
@bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
🔖 1 ❤️ 23 🔁 9 👁 2,869
Solange Peters @peters_solange
RT @OncoAlert: 🫁 When adding another immunotherapy agent sounds promising—but the phase III data say otherwise—what should we learn?
https://t.co/MZfaljl0PP
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation
SKYSCRAPER-03 compared tiragolumab plus atezolizumab with durvalumab as consolidation therapy after chemoradiation for unresectable stage III #NSCLC ➡️In PD-L1–positive patients, progression-free survival was 19.4 versus 16.6 months, but the difference was not statistically significant.
✅ Overall survival was also similar between groups, with no new safety concerns. The primary endpoint was not🚫 met, indicating that adding tiragolumab did not provide additional benefit over durvalumab. #LungCancer
@DrSanjayPopat
@karenkellymd
@BairdAM
@MLJohnsonMD2
@k_cupp_
Pinging 🚨OncoAlert Faculty
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
@bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
🔖 1 ❤️ 23 🔁 9 👁 2,869
OncoAlert @OncoAlert
🫁 When adding another immunotherapy agent sounds promising—but the phase III data say otherwise—what should we learn?
https://t.co/MZfaljl0PP
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation
SKYSCRAPER-03 compared tiragolumab plus atezolizumab with durvalumab as consolidation therapy after chemoradiation for unresectable stage III #NSCLC ➡️In PD-L1–positive patients, progression-free survival was 19.4 versus 16.6 months, but the difference was not statistically significant.
✅ Overall survival was also similar between groups, with no new safety concerns. The primary endpoint was not🚫 met, indicating that adding tiragolumab did not provide additional benefit over durvalumab. #LungCancer
@DrSanjayPopat
@karenkellymd
@BairdAM
@MLJohnsonMD2
@k_cupp_
Pinging 🚨OncoAlert Faculty
@peters_solange
@christine_lovly
@GlopesMd
@DrSanjayPopat
@StephenVLiu
@HenningWillers
@HHorinouchi
@BRicciutiMD
@PercyLeeMD
@jillfeldman4
@bensolomon1
@Latinamd
@DrJNaidoo
@barlesi
@UOzkerim
@FernandoOnco
@DrMirallas
@VanitaNoronha
@NarjustFlorezMD
@MartinReck2
🔖 1 ❤️ 23 🔁 9 👁 2,869
Oncology Brothers @OncBrothers
RT @RManochakian: 🔥🚨@OncoAlert Hot off the press.
‼️@JazzPharma plans to ask @US_FDA to withdraw:
👎🏻🛑#Lurbinectedin (#Zepzelca) approval in 2nd line Tx of #SmallCell #LungCancer (#SCLC).
This is based on #Negative #Lagoon phase 3 trial that showed NO #OS benefit.
👇🏻
https://t.co/XtpPBWXT7s https://t.co/hxU8kEb6U4
🔖 4 ❤️ 36 🔁 11 👁 7,351
Masahiro TORASAWA, MD. PhD. @M_Torasawa
【Osimertinib With or Without Chemotherapy in Advanced NSCLC With EGFR and Concurrent TP53 Mutations】
🇨🇳 Multicenter, randomized, open-label, phase 3 study
📚 JAMA 2026
https://t.co/x7liXNPCFY
🔑 Key Results
🚀 Osi+chemo improved PFS compared to Osi alone in EGFR/TP53 co-mutated NSCLC (median 34.0 vs 15.6 months, HR 0.44, P<0.001)
📈 Median Duration of Response more than doubled (32.7 vs 15.3 months) with a positive trend in OS
🎯 Consistent benefit across all subgroups, including patients with brain metastases
🔖 30 ❤️ 51 🔁 8 👁 4,123
OncLive.com @OncLive
🚨 Zipalertinib plus chemo just met its primary PFS end point in the phase 3 REZILIENT3 trial for first-line EGFR exon 20 insertion+ NSCLC vs chemo alone. Full breakdown 👇 #lcsm
https://t.co/JQsiqvBcoP
🔖 0 ❤️ 3 🔁 1 👁 550
ClinicalOncologyNews @ClinOncNews
FDA approves zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive NSCLC after prior ROS1 TKI therapy. In ARROS-1, the ORR was 44%, with many responses lasting ≥12 months: https://t.co/66FEsAxiy9 #LungCancer https://t.co/UAs972ZUIj
🔖 0 ❤️ 0 🔁 0 👁 63
Hossein Borghaei, DO @HosseinBorghaei
RT @StephenVLiu: Nature publication today from Dr. Tina Cascone et al with tremendous detail on biomarkers from CheckMate 77T predicting benefit from perioperative nivolumab in patients with resectable NSCLC. Amazing amount of detailed data in this @Nature paper.
https://t.co/Sb0H4YOpxz
🔖 54 ❤️ 116 🔁 39 👁 13,392
Jason Luke, MD, FACP, FASCO @jasonlukemd
RT @StephenVLiu: Nature publication today from Dr. Tina Cascone et al with tremendous detail on biomarkers from CheckMate 77T predicting benefit from perioperative nivolumab in patients with resectable NSCLC. Amazing amount of detailed data in this @Nature paper.
https://t.co/Sb0H4YOpxz
🔖 54 ❤️ 116 🔁 39 👁 13,392
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.